Evidence mapPaperPMID 33344651Full record

ArticleJournal of diabetes research2020

Radix Rehmanniae and Corni Fructus against Diabetic Nephropathy via AGE-RAGE Signaling Pathway.

Jing Chen, Yuping Chen, Anmei Shu, Jinfu Lu, Qiu Du, Yuwei Yang, Zhiyang Lv, Huiqin Xu

Abstract read
In one paragraph

Article in Journal of diabetes research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Research progress of coumarins and their derivatives in the treatment of diabetes.Journal of enzyme inhibition and medicinal chemistry · 2022
    Review
  13. Effects of Ziyin Qianyang Formula on Renal Fibrosis through the TGF-Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing ChenHanlin College, Nanjing University of Chinese Medicine, Taizhou 225300, China.
Yuping ChenDepartment of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Anmei ShuDepartment of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Jinfu LuDepartment of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Qiu DuDepartment of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Yuwei YangHanlin College, Nanjing University of Chinese Medicine, Taizhou 225300, China.
Zhiyang LvHanlin College, Nanjing University of Chinese Medicine, Taizhou 225300, China.ORCID https://orcid.org/0000-0003-3212-5310
Huiqin XuDepartment of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.ORCID https://orcid.org/0000-0001-8775-4099

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsRadix Rehmanniae and Corni Fructus (RC) have been widely applied to treat diabetic nephropathy (DN) for centuries. But the mechanism of how RC plays the therapeutic role against DN is unclear as yet.

methodsThe information about RC was obtained from a public database. The active compounds of RC were screened by oral bioavailability (OB) and drug-likeness (DL). Gene ontology (GO) analysis was performed to realize the key targets of RC, and an active compound-potential target network was created. The therapeutic effects of RC active compounds and their key signal pathways were preliminarily probed via network pharmacology analysis and animal experiments.

resultsIn this study, 29 active compounds from RC and 64 key targets related to DN were collected using the network pharmacology method. The pathway enrichment analysis showed that RC regulated advanced glycosylation end product (AGE-) RAGE and IL-17 signaling pathways to treat DN. The animal experiments revealed that RC significantly improved metabolic parameters, inflammation renal structure, and function to protect the kidney against DN.

conclusionsThe results revealed the relationship between multicomponents and multitargets of RC. The administratiom of RC might remit the DM-induced renal damage through the AGE-RAGE signaling pathway to improve metabolic parameters and protect renal structure and function.

Indexed as

CornusRehmanniaAnimalsAnti-Inflammatory AgentsDiabetic NephropathiesDisease Models, AnimalDrugs, Chinese HerbalGlycation End Products, AdvancedHypoglycemic AgentsInterleukin-17KidneyMaleMice, Inbred C57BLPlant RootsReceptor for Advanced Glycation End ProductsSignal TransductionAger protein, mouseAnti-Inflammatory AgentsDrugs, Chinese HerbalGlycation End Products, AdvancedHypoglycemic AgentsInterleukin-17Receptor for Advanced Glycation End Products

Identifiers

PMID33344651
PMCPMC7725584

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.